Business Intelligence

Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.

Cooper University Health Care Selects Sectra’s Subscription Model for Enterprise Imaging

SHELTON, Conn., July 26, 2022 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will install its enterprise imaging system at Cooper University Health Care.

Silicon Valley POCUS supplier buys Canadian AI ultrasound simplifier

Point-of-care ultrasound innovator Exo has acquired Medo AI of Edmonton, Alberta, with plans to soon make ultrasound imaging “as easy as snapping a photo on a smartphone.”

Social media for radiology residency: The surface is well-scratched, but there’s room and reason to delve deeper

Twitter is tops for diagnostic radiology residency programs using social media for education, networking and/or trainee recruitment.

5 ways to financially thrive in the face of chronic little pay cuts

Radiology researchers from six leading medical schools have laid out some attuned and readily adoptable strategies for groups challenged to prosper in a time of difficult reimbursement dynamics.

Thumbnail

FDA clears AI assessor of stricken dense brain tissue

An AI startup has received the FDA’s go-ahead to market a new tool within its existing platform that automatically diagnoses stroke and brain injury in hyperdense brain tissue imaged with unenhanced CT.

Imaging industry news bites of the week

Radiology business developments that broke softly but may make waves

New PET imager cleared for U.S. sales

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

Generic CT contrast supplier pledges ‘immediate relief’ from shortage

A global tech and pharma vendor is set to inject U.S. healthcare with a set of generic contrast agents, the first of which will be an FDA-approved substitute for GE Healthcare’s Visipaque.